Neuroscience

Neurons
#Anxiety disorder #Neurology #Neuroscience #Tokyo University of Science

Scientists identify potential new therapeutic target for anxiety

A new study has highlighted the role of specific neuronal circuits in the brain involved in the development of anxiety, and distinct mechanisms of action of the therapeutic delta opioid receptor (DOP) agonist KNT-127. Understanding the neural circuits and molecular mechanisms that trigger anxiety can aid… Read More

#News

Protein degrader
#Arvinas #Neurodegenerative disorders #Phase I trial #PROTAC #Protein degradation

PROTAC degrader for neurodegeneration enters trials

Arvinas has commenced dosing in the Phase I clinical trial of ARV-102, its first oral PROTAC (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases. In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade leucine-rich repeat kinase 2 (LRRK2), which… Read More

#News

Tau proteins
#Alzheimer's #Gene therapy #Preclinical investigations #Tau protein #Voyager Therapeutics

New data validates tau silencing gene therapy for Alzheimer’s

Voyager Therapeutics has announced new data from its two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease. Data on VY-TAU01, Voyager’s lead anti-tau antibody candidate, and on Voyager’s tau silencing gene therapy programme will be presented at the upcoming 2024 International Conference on Alzheimer’s and… Read More

#Editor's Choice #News

Laboratory informatics
#AI / data analytics / healthtech / informatics #Data management #Neurodegenerative disorders #Screening

Informatics helps virtual biotech bring compound to clinical trial

This article is sponsored by Collaborative Drug Discovery. Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. The Libra portfolio includes three small molecule programmes, including their lead non-clinical programme targeting TRPML1 (based on… Read More

#News

Neurones in the brain
#Alzheimer's #Gene editing #Neurodegenerative disorders #Neuroscience

Advances in neuroscience drug discovery

Listen to this article on the DDW Podcast: Lu Rahman looks at neuroscience drug discovery – advances and challenges – and how breakthroughs in this field are helping address areas of unmet need.  Recent advances in biomarkers, research into the central nervous system and breakthroughs in human iPSC cell models, have bolstered… Read More

#Exclusive Content

#Alzheimer's #Cell therapy #Natural killer cells #Neurodegenerative disorders #NKGen #Phase I trial

The killer instinct: Using natural killer therapy to treat Alzheimer’s

DDW Editor Reece Armstrong speaks to Dr Paul Song, MD, NKGen and Dr Vince DeOrchis, clinician, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s. In October 2023, pharmaceutical company NKGen Biotech released data from its… Read More

#Exclusive Content

Neuroscience Parkinson's disease
#Clinical trials #Gain Therapeutics #Neuroscience #Parkinson's

Restored motor function in mouse models of Parkinson’s disease  

Gain Therapeutics has announced preclinical data demonstrating that its clinical-stage GCase regulator GT-02287 provided neuroprotection and restored motor function in Parkinson’s disease models following delayed administration.   The data were accepted as a late-breaker abstract and was presented at the 20th Annual WORLDSymposium.  “We… Read More

#News

#Clinical trial design #Dementia #Funding #Neurodegenerative disorders #University College London

UK dementia research gets £49.9 million funding boost

Head of clinical trials at the University College London (UCL) Dementia Research Centre, Dr Cath Mummery, has been announced as the Director of a new network of dementia trial sites across the country. The UK government has authorised £49.9 ($63.4) million of new funding to improve… Read More

#Editor's Choice #News

Neuroscience
#Cerebrotendinous xanthomatosis #Funding #Gene therapy #Neurodegenerative disorders #Neuroscience #Vivet Therapeutics

Funds advance gene therapy for cerebrotendinous xanthomatosis 

Vivet Therapeutics has received €4.9 million from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease.   This funding is from the “Innovations in biotherapies” framework of the France Health Innovation Plan 2030 and specifically the acceleration strategy… Read More

#Business & Investment #News

Brain physiology
#Clinical trials #European Medicines Agency #Neuroscience #Synendos Therapeutics

EMA approves endocannabinoid system modulator trial

Synendos Therapeutics, has received approval from the European Medicines Agency (EMA) to commence the Phase I first-in-human clinical trial of its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the endocannabinoid system (ECS) to restore healthy brain physiology.   The randomised, double-blind, placebo-controlled study will… Read More

#News #Regulatory

Traumatic brain injury
#Brain injury #Neuroscience #Plant-based #Psychiatry #PTSD #Stanford University

Plant-based psychoactive drug treats traumatic brain injury

New research has found that plant-based psychoactive drug ibogaine improved depression, anxiety and functioning among veterans with traumatic brain injuries (TBI). TBI from head trauma or blast explosions are a leading cause of post-traumatic stress disorder (PTSD), anxiety, depression and suicide among veterans. Stanford… Read More

#News #Trending News

AI clinical trials concept
#AI / data analytics / healthtech / informatics #ALS #Artificial intelligence (AI) #Verge Genomics #Wearable tech

AI-discovered ALS drug trial uses unique remote monitoring

Verge Genomics has initiated a Phase Ib proof-of-concept study for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS) with VRG50635. VRG50635 is a small molecule PIKfyve inhibitor and is reportedly one of the first drugs to enter clinical trials that was entirely… Read More

#Editor's Choice #News

Human brain
#Age-related diseases (ARDs) #Dementia #Gene mutation #Neurodegenerative disorders #Organoids

Organoid research sheds light on gene mutation linked to dementia

New understanding of a gene that is linked to some forms of dementia and other age-related diseases gives scientists fresh hope that action can be taken against these diseases long before the onset of symptoms. The gene – called Angiogenin or ANG – is associated with… Read More

#Editor's Choice #News

Human brain
#Clinical trial #Neuroscience #Newron Pharmaceuticals #Schizophrenia #Treatment resistance

“Highly encouraging” results for schizophrenia drug

Milan-based Newron Pharmaceuticals has reported “exceptional” one-year results from study 014/15 into evenamide as an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS). The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of… Read More

#News

Parkinson's disease
#Charity #Funding #IRLAB Therapeutics #Parkinson's #The Michael J Fox Foundation

Parkinson’s charity awards $2m to support apathy treatment

Swedish company IRLAB Therapeutics has been awarded funding of over $2 million from The Michael J Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to conduct a Phase I clinical study of IRL757, a drug candidate in development as a novel treatment of… Read More

#News

#Cancer research #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Neuroscience #Oncology

DDW readers’ top drug discovery developments of 2023

DDW’s Diana Spencer takes a look at the breaking news stories that were most popular with DDW readers over the last year. Representing a dominant field of drug discovery, it isn’t surprising that breakthroughs in cancer research were popular with DDW readers in 2023, particularly strategies to overcome treatment resistance… Read More

#Exclusive Content